Group 1 - The core announcement is that Basilea Pharmaceutica's drug, Pralsetinib (brand name GAVRETO), has been included in China's National Medical Insurance catalog, effective January 1, 2026 [1] - Pralsetinib is an oral targeted therapy approved for treating adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and other specific thyroid cancers [1][2] - The drug has already received approval in Hong Kong and Taiwan for similar indications, expanding its market presence in Greater China [1] Group 2 - The FDA has approved GAVRETO for the treatment of adult patients with metastatic RET fusion-positive NSCLC and certain thyroid cancers, indicating its acceptance in the U.S. market [2] - Basilea Pharmaceutica holds exclusive development and commercialization rights for Pralsetinib in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [2] - In November 2023, Basilea Pharmaceutica granted exclusive commercialization rights for Pralsetinib in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [2]
基石药业-B(02616)：普吉华®(普拉替尼胶囊)获纳入2025年国家医保目录